ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

By News Medical May 15, 2026 #Approaches, #Approved, #comparator, #concentrations, #Data, #EMRX101, #ExiVex, #Faster, #Health, #inhuman, #intranasal, #IVlike, #Medical, #medicine, #naloxone, #peak, #pharmacokinetic, #plasma, #reports, #showing, #substantially, #Tmax

ExiVex Biopharma (formerly EmerRx Biopharma), a clinical-stage pharmaceutical company developing a proprietary dual-chamber intranasal drug delivery platform, today announced in-human pharmacokinetic (PK) data for its lead candidate EMRX-101, an intranasal naloxone product targeting opioid-induced respiratory depression.

By News Medical

Simple physical function tests may identify adults at mobility risk

ExiVex reports in-human pharmacokinetic data showing EMRX-101 intranasal naloxone approaches IV-like peak plasma concentrations with substantially faster Tmax than currently approved comparator

Dark Matter May Have Left Its Fingerprint in a Gravitational Wave.

Artemis III: The Mission That Has to Work Before Humans Can Return to the Moon.